Browse studies

Find your next paid study

17 recruiting studies matching your filters

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-021 as a Single Agent and in Combination Therapy in Patients With Advanced Solid Tumors

This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and a…

Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast Cancer+6 more

Estimated

~$10 – $8,750

Avenzo Therapeutics, Inc.NCT05867251

Phase 1

A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The m…

Advanced Solid TumorsHNSCCSCLC+3 more

Estimated

~$10 – $8,750

Tubulis GmbHNCT06657222

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal res…

Breast CancerTNBC - Triple-Negative Breast CancerHR Positive/HER-2 Negative Breast Cancer+2 more

Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer

This is a single-arm and single site phase II trial combination of chemotherapy and pembrolizumab with LBP MO-03 in 50 trial participants with early triple neg…

TNBC - Triple-Negative Breast CancerTNBCEarly Stage Triple-Negative Breast Carcinoma

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early Stage Triple Negative Breast Cancer

This is a single arm phase II trial combination of ivonescimab and carbo-docetaxel every 3 weeks for 6 cycles in patients with early-stage triple negative brea…

TNBCTNBC - Triple-Negative Breast CancerEarly Stage Triple-Negative Breast Carcinoma

Estimated

~$10 – $6,250

Cedars-Sinai Medical CenterNCT07017673

Phase 3

A Randomized, Phase 3 Trial of SRG-514 Administered Intraoperatively to the Site of Tumor Resection in Patients Undergoing Breast-Conserving Surgery for Triple Negative Breast Cancer

This is a Phase 3 trial to compare SRG-514 (active pharmaceutical ingredient \[API\]: ketorolac) administered intraoperatively to the tumor resection cavity wi…

TNBC - Triple-Negative Breast Cancer

Estimated

~$10 – $8,750

SURGE TherapeuticsNCT07723469

Phase 1

A Phase 1 Study of BAL0891 as Monotherapy and in Combination With Chemotherapy or Tislelizumab in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, a…

Advanced Solid TumorTNBC - Triple-Negative Breast CancerGastric Cancer+1 more

Estimated

~$10 – $8,750

SillaJen, Inc.NCT05768932

Phase 2

Phase II Trial of Alpelisib With iNOS Inhibitor and Nab-paclitaxel in Patients With HER2 Negative Metastatic or Locally Advanced Metaplastic Breast Cancer (MpBC)

This is a research study to test the safety and effectiveness of using the drug alpelisib together with chemotherapy (nab-paclitaxel) and a drug called L-NMMA …

HER2-negative Breast CancerMetastatic Breast CancerMetaplastic Breast Carcinoma+1 more

Estimated

~$10 – $6,250

The Methodist Hospital Research InstituteNCT05660083

Phase 1

Pilot Trial of the IL-4 Receptor Antagonist Dupilumab Plus Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Pilot trial of the IL-4 receptor antagonist dupilumab plus pembrolizumab, paclitaxel, and carboplatin in locally advanced triple negative breast cancer (TNBC).…

Locally Advanced Triple Negative Breast CancerTNBC - Triple-Negative Breast Cancer

Estimated

~$10 – $7,500

Rima PatelNCT06637306

Role of the Immune Environment in Response to Therapy in Breast Cancer

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be comp…

Breast CancerER Positive Breast CancerHER2-negative Breast Cancer+1 more

Estimated

~$10 – $750

Abramson Cancer Center at Penn MedicineNCT05396612

Phase 2

IIT2021-01-Shiao-CSF1Ri: Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

This is an open-label prospective, single institution, Phase II study of pembrolizumab in combination with radiation therapy and CSF-1R inhibition in patients …

TNBC - Triple-Negative Breast CancerBreast Cancer

Estimated

~$10 – $7,500

Stephen ShiaoNCT05491226

Phase 2

Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Immunotherapy Combinations for the Augmentation of Immune Responses

The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatmen…

Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerBreast Cancer+1 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT04683679